Clinical Trial Update: Two-week Course Versus Conventionally Fractionated Chemoradiotherapy in Rectal Cancer [Phase 3]

View source ↗

Summary

This entry updates a Phase 3 trial comparing a two-week course of chemoradiotherapy with conventional fractionated chemoradiotherapy for rectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Snippet

Sponsor: Jong Hoon Lee | Conditions: Response to Toxin, Toxicity | Phase 3 | Status: UNKNOWN